Literature DB >> 25455277

Alternative donor transplantation for adults with acute leukemia.

Frederick R Appelbaum1.   

Abstract

Allogeneic hematopoietic cell transplantation (HCT) from a matched related donor (MRD) is the preferred therapy for many adults with acute leukemia. Yet most patients do not have matched siblings, and the numbers who do will continue to drop as the average number of children per couple in the United States continues to decline. Recent reports show little difference in the outcomes of matched related and matched unrelated transplants for acute leukemia. Additionally, survival rates at 3-5 years after transplant appear to be generally similar following matched related, matched unrelated, single antigen mismatched unrelated, double cord blood and, perhaps even after haplo-identical transplants. Nevertheless, there are differences between stem cell sources that should be considered in the choice of donor. The following review provides some perspective on the identification of the best stem cell sources for patients who do not have matches within their families.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  acute lymphoblastic leukemia; acute myeloid leukemia; graft versus host disease; hematopoietic cell transplantation; matched related donor; matched unrelated donor; mismatched unrelated donor; umbilical cord blood

Mesh:

Year:  2014        PMID: 25455277     DOI: 10.1016/j.beha.2014.10.009

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  6 in total

1.  Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission in the Absence of a Matched Identical Sibling: A Meta-Analysis.

Authors:  Zhichao Li; Yinmei Liu; Qing Wang; Linjun Chen; Liyuan Ma; Siguo Hao
Journal:  Acta Haematol       Date:  2019-02-26       Impact factor: 2.195

2.  Successful haploidentical transplantation using plasma exchange and post-transplantation cyclophosphamide for severe aplastic anemia patients with anti-human leukocyte antigen donor-specific antibodies.

Authors:  Junjie Cao; Renzhi Pei; Pisheng Zhang; Xuhui Liu; Dong Chen; Xiaohong Du; Lieguang Chen; Tiantian Wang; Peipei Ye; Ying Lu
Journal:  Ann Hematol       Date:  2021-07-06       Impact factor: 3.673

3.  The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis.

Authors:  Lorenz Selberg; Peter Stadtherr; Sascha Dietrich; T Hien Tran; Thomas Luft; Ute Hegenbart; Andrea Bondong; Julia Meissner; Nora Liebers; Michael Schmitt; Anthony Dick Ho; Carsten Müller-Tidow; Peter Dreger
Journal:  Bone Marrow Transplant       Date:  2020-06-18       Impact factor: 5.483

Review 4.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report.

Authors:  Bronwen E Shaw; Theresa Hahn; Paul J Martin; Sandra A Mitchell; Effie W Petersdorf; Gregory T Armstrong; Nonniekaye Shelburne; Barry E Storer; Smita Bhatia
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-30       Impact factor: 5.742

5.  Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program.

Authors:  Fan Yang; Daopei Lu; Yu Hu; Xiaojun Huang; He Huang; Jing Chen; Depei Wu; Jianmin Wang; Chun Wang; Mingzhe Han; Hu Chen
Journal:  Ann Transplant       Date:  2017-06-27       Impact factor: 1.530

6.  Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.

Authors:  John M Pagel; Megan Othus; Guillermo Garcia-Manero; Min Fang; Jerald P Radich; David A Rizzieri; Guido Marcucci; Stephen A Strickland; Mark R Litzow; M Lynn Savoie; Stephen R Spellman; Dennis L Confer; Jeffrey W Chell; Maria Brown; Bruno C Medeiros; Mikkael A Sekeres; Tara L Lin; Geoffrey L Uy; Bayard L Powell; Ruthee-Lu Bayer; Richard A Larson; Richard M Stone; David Claxton; James Essell; Selina M Luger; Sanjay R Mohan; Anna Moseley; Harry P Erba; Frederick R Appelbaum
Journal:  JCO Oncol Pract       Date:  2020-01-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.